
French pharmaceutical company Sanofi has published its fiscal report for Q4 2020, and even though the firm reports a 4.2-percent growth in sales for the business leg over the course of the fourth quarter, the picture is less rosy in view of the diabetes business.
The French firm has registered a total 8.4-percent decline in the diabetes business, which brings the revenue for the year's final quarter to EUR 1.087bn (USD 1.3bn).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app